Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Labetalol in Preeclampsia with Severe Features
NCT03872336Phase 4Terminated
- Sponsor
- Albany Medical College
- Start
- Feb 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in preeclampsia comparing Experimental labetalol dose with Current standard of care (2 arms). Primary endpoint: Time to blood pressure control at 4 hours. Started Feb 2019; status: terminated.
02
Drugs
labetalol
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT03872336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872336.